The UroNav fusion biopsy system is an innovative technology that uses a combination of MRI and ultrasound images for multi-parametric localization and targeted biopsy of the prostate. Unlike the traditional ultrasound-only based approach that takes multiple “blind” samples (and only yields successful detection rates in the 30th percentile), UroNav allows urologists to specifically target the Regions of Interest (ROI) identified with a previously performed MRI scan. The device functions similar to a GPS system in finding suspected cancerous areas within the prostate gland guiding the physician to the ROIs for a precise biopsy. The result is prostate cancer detection rates approaching 80 to 90 percent. In many cases, this technique may negate the need for multiple biopsies endured over a prolonged period of time. Patients can now benefit from a more accurate and reliable biopsy when prostate cancer is present and more confidence in a negative biopsy result when it is not.
"I think the use of the UroNav fusion biopsy technology is going to significantly improve the precision of prostate cancer diagnosis and allow us to further personalize the management of each individual’s prostate cancer. I am very excited and proud to be able to provide this cutting edge technology at Kasraeian Urology, bringing the highest level of advanced diagnostics to the patients here in Jacksonville and beyond."
Ali Kasraeian, M.D., F.A.C.S.
Cost of Procedure
Fortunately, insurance covers the cost of the procedure and the MRI for most patients. If there is an out-of-pocket expense, it is rarely more than $200-$300. This investment is nothing compared to the peace of mind you gain in knowing that you utilized the most advanced and accurate prostate cancer detection equipment available.
How It Compares
The technology utilized by the Invivo Fusion biopsy system is the most advanced, most precise tool available for prostate biopsies. A traditional biopsy is the equivalent of throwing darts with a blind fold on while the fusion biopsy is as if you’re throwing from 2 feet away. A recent study demonstrated a 23% advantage of sampling high-risk MRI sites by a targeted approach vs 12-core traditional sampling (53% + rate with fusion vs 30% + rate traditional biopsy). When stratified by MRI risk, intermediate and high risk detection rates were 67% and 89% respectively – improved vs current standards. MRI appeared to detect more cancer per core as well.